GlassScriptPhysician profile
Jeanie L Mccormack
NPI 1508043274
$8,523.03
in general payments reported to CMS, 2019-2025
43 companies · $1,416 in 2025
The $1,416 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,177 · 2020: $475 · 2021: $1,114 · 2022: $950 · 2023: $1,125 · 2024: $2,266 · 2025: $1,416.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,491 · Education: $316.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,490.86 |
| Education | $316.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $1,783.94 | 2019-2025 | Mavenclad, Mavenclad |
| Abbvie INC. | $1,736.85 | 2021-2025 | |
| Teva Pharmaceuticals USA, INC. | $783.44 | 2019-2025 | Austedo Xr, Austedo, Austedo Xr |
| Novartis Pharmaceuticals Corporation | $513.03 | 2019-2025 | |
| Pfizer INC. | $374.45 | 2023-2025 | |
| Lilly USA, LLC | $351.17 | 2019-2025 | Emgality, Reyvow, Amyvid |
| Ucb, INC. | $343.99 | 2019-2025 | Briviact, Fintepla |
| Mdd US Operations, LLC | $297.77 | 2019-2025 | Gocovri |
| Amgen INC. | $227.09 | 2019 | |
| Neurocrine Biosciences, INC. | $196.46 | 2019-2025 | Ingrezza |
| Biogen, INC. | $190.79 | 2019-2025 | Vumerity |
| Livanova USA, INC. | $165.29 | 2019-2023 | Vns Therapy Sentiva Model 1000 Generator |
| Acadia Pharmaceuticals INC | $157.26 | 2019-2024 | Nuplazid |
| Supernus Pharmaceuticals, INC. | $132.44 | 2020-2025 | Qelbree |
| Genentech USA, INC. | $113.15 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
Show all 43 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeanie Mccormack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.